<DOC>
	<DOCNO>NCT01974518</DOCNO>
	<brief_summary>The purpose study compare effectiveness rituximab alone vs combination rituximab cyclophosphamide treatment pemphigus respond adequately routine medication .</brief_summary>
	<brief_title>Comparative Study Rituximab Versus Combination Rituximab Intravenous Cyclophosphamide Severe Pemphigus</brief_title>
	<detailed_description />
	<mesh_term>Pemphigus</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Patients diagnosis pemphigus base clinical , histopathological immunological feature follow : Refractory disease define continue extension old lesion , development new lesion , failure establish lesion begin heal despite 3 week therapy 1.5 mg/kg/day prednisolone equivalent without concurrent use cyclophosphamide 2mg/kg/day 12 week azathioprine 2.5 mg/kg/day 12 week . Patients fail respond 6 DCP/DP also consider refractory disease . Infections Hepatitis B , Hepatitis C , HIV , active tuberculosis sepsis . Abnormal liver function test renal function test Known cardiac arrhythmia conduction abnormality Systolic ejection fraction &lt; 40 % Pregnancy breast feed Severely decrease bone marrow function . Known history bladder cancer hemorrhagic cystitis Known allergy cyclophosphamide Patients reproductive age group n't complete family Known hypersensitivity murine protein . Patients consent study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Pemphigus</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Rituximab IV cyclophosphamide combination</keyword>
	<keyword>B cell re-population characteristic follow Rituximab</keyword>
</DOC>